Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn’s disease: 2-year results from the U-ENDURE Long-Term Extension study
Edward V. Loftus(Mayo Clinic), Irina Blumenstein(Goethe University Frankfurt), Hiroshi Nakase(Sapporo Medical University), Fernando Aponte(AbbVie (United States)), Colla Cunneen(AbbVie (United States)), Vipul Jairath(McMaster University), Samuel I. Anyanwu(AbbVie (United States)), Elena Dubcenco(AbbVie (United States)), Fernando Magro(Universidade do Porto), Sharanya Ford(AbbVie (United States)), Geert D’Haens(Amsterdam University Medical Centers), Feng Tian(Sun Yat-sen University), Édouard Louis(Centre Hospitalier Universitaire de Liège), Benjamin Duncan(AbbVie (United States)), Miguel Regueiro(University of Pittsburgh Medical Center), Irina Fish(AbbVie (United States)), Jenny Griffith(AbbVie (United States)), Ana Paula Lacerda(AbbVie (United States))
Cited by 8
Related Papers
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
|Nature Genetics|2011|1.4k
The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis
|International Journal of Molecular Sciences|2017|916
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
|Gastroenterology|1998|865